Evidence map›Paper›PMID 19728750›Full record

SynthesisDrugs & aging2009

NSAID use and the risk of Parkinson's disease: systematic review and meta-analysis of observational studies.

Ali Samii, Mahyar Etminan, Matthew O Wiens, Siavash Jafari

Registry-linked trialAbstract readMeta-AnalysisSystematic Review
PubMed Publisher
In one paragraph

Synthesis in Drugs & aging, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06816810 (TALLman Family Energizes Research To Help Alleviate Neuroinflammation in Parkinson's Disease - "TALLER THAN PD." A Phase 2 Futility Study to Evaluate the Efficacy, Safety and Tolerability of Hydroxychloroquine in Subjects With Early Treated Parkinson's Disease), which is not on this map. Cited by 80 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
80citing papers in PubMed, 5 pooled it
8.7field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06816810 phase2not yet recruitingnot on this mapstarted 2025, after this paper: background citation

TALLman Family Energizes Research To Help Alleviate Neuroinflammation in Parkinson's Disease - "TALLER THAN PD." A Phase 2 Futility Study to Evaluate the Efficacy, Safety and Tolerability of Hydroxychloroquine in Subjects With Early Treated Parkinson's Disease

TypeinterventionalSponsorOttawa Hospital Research InstituteRan2025 to 2027Enrolled40ConditionsParkinson&Amp, #39, s DiseaseArmsHydroxychloroquine (HCQ)
3 · Its place in the literature

Who cites it

80 citing papers in PubMed, 5 syntheses or guidelines pooled it, 160 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Review
  7. Research progress on intranasal treatment for Parkinson's disease.Neuroprotection (Chichester, England) · 2024
    Review
  8. Review
  9. Article
  10. Article
  11. Brain and Systemic Inflammation in De Novo Parkinson's Disease.Movement disorders : official journal of the Movement Disorder Society · 2023
    Article
  12. Review
  13. Article
  14. Review
  15. Review
  16. Bilirubin Prevents the THInternational journal of molecular sciences · 2022
    Article
  17. Review
  18. Article
  19. Review
  20. Article

20 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Ali SamiiDepartment of Neurology, University of Washington, and the Seattle VA Parkinson Disease Research Education and Clinical Center, Seattle, Washington, USA. asamii@u.washington.edu
Mahyar Etminan
Matthew O Wiens
Siavash Jafari
University of British Columbia · CAUniversity of Washington · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSeveral studies have suggested that NSAID use may modify the risk of developing Parkinson's disease (PD).

objectiveOur aim was to conduct a meta-analysis of observational studies evaluating NSAID use and the risk of PD.

methodsWe systematically searched MEDLINE (1966-November 2008), EMBASE (1980-November 2008) and other databases. Data from 11 studies were included in the meta-analysis. We used the random effects model to calculate risk ratios (relative risks) and their corresponding 95% confidence intervals (CIs).

resultsThe pooled risk ratio of PD with NSAID use was 0.95 (95% CI 0.80, 1.12). The pooled risk ratio of PD with high-dose or long-duration NSAID use was 0.91 (95% CI 0.78, 1.05). The pooled risk ratio of PD for aspirin (acetylsalicylic acid) users was 1.08 (95% CI 0.93, 1.26). The pooled risk ratio of PD among ibuprofen users was 0.76 (95% CI 0.65, 0.89). The pooled risk ratio of PD in men using NSAIDs was 0.79 (95% CI 0.69, 0.92), and in women using NSAIDs, it was 0.72 (95% CI 0.45, 1.15).

conclusionsNSAIDs as a class do not seem to modify the risk of PD. However, ibuprofen may have a slight protective effect in lowering the risk of PD. Although the risk ratios of PD in male and female NSAID users were similar, the 95% CI for men was suggestive of a slight risk reduction.

Indexed as

AgedAnti-Inflammatory Agents, Non-SteroidalAspirinCase-Control StudiesCohort StudiesConfidence IntervalsFemaleHumansIbuprofenMaleMiddle AgedNeuroprotective AgentsOdds RatioParkinson DiseaseRandomized Controlled Trials as TopicRiskAnti-Inflammatory Agents, Non-SteroidalAspirinIbuprofenNeuroprotective Agents

Identifiers

PMID19728750
OpenAlexW2084506085

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.